This trial is testing a new medication, BMS-986253, in combination with other drugs, to see if it can help treat advanced cancers.
4 Primary · 19 Secondary · Reporting Duration: Approximately 5 years
5 Treatment Groups
Part 2A: BMS-986253 + nivolumab + ipilimumab
1 of 5
Part 1A: BMS-986253 + nivolumab
1 of 5
Part 1B: BMS-986253 + nivolumab
1 of 5
Part 1C: BMS-986253 + nivolumab + ipilimumab
1 of 5
Part 2B: Placebo + nivolumab + ipilimumab
1 of 5
372 Total Participants · 5 Treatment Groups
Primary Treatment: BMS-986253 · Has Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How is BMS-986253 typically employed in medical practice?
"BMS-986253 is frequently used to counteract the effects of anti-angiogenic therapy. It has also been proven effective in treating a range of malignancies, from unresectable melanoma to squamous cell carcinoma." - Anonymous Online Contributor
What other investigations have been conducted with regards to BMS-986253?
"BMS-986253 was researched for the first time in 2009 at Texas Children's Hospital. To date, 18672 trials have been completed and 765 are actively recruiting individuals to participate. Notably, a substantial number of these studies can be found around Montréal, Georgia." - Anonymous Online Contributor
How many individuals have enrolled in this trial?
"To ensure the success of this research, a total of 372 participants that meet all inclusion criteria must be recruited. Potential recruits can find locations in Montréal, Georgia and Marietta, California." - Anonymous Online Contributor
Are there any vacancies for participants in this medical experiment?
"The details of the trial, which were first made public on February 12th 2018 and updated on November 28th 2022, are still available for potential participants to view via clinicialtrials.gov." - Anonymous Online Contributor
What expectations has this trial set for its results?
"This long-term trial, which is expected to last approximately 5 years, aims to measure the primary outcome of adverse events meeting pre-determined dose limiting toxicities (DLT) criteria. Secondary objectives include progression free survival hazard ratio based on Blinded Independent Central Review (BICR) assessments per Response Evaluation Criteria in Solid Tumours v1.1 as well as incidence of death and clinically significant changes in clinical laboratory results from urinalysis tests." - Anonymous Online Contributor
How many facilities within the state are running this research effort?
"This experimental trial is conducted out of Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies in Montréal, Georgia, Local Institution - 0056 in Marietta, California, and Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital in Los Angeles. Additionally there are 43 other clinical sites participating across the US." - Anonymous Online Contributor